Search results for PDGFR

Biotin Anti-PDGFR alpha antibody [16A1], Abcam, AB99924

The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.

Biotin Anti-PDGFR beta antibody [APB5], Abcam, AB93533

Anti-PDGFR alpha antibody [EPR22059-270], Abcam, AB203491

Anti-PDGFR alpha antibody [EPR22059-270] (ab203491) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, I-ELISA, ICC/IF, IHC-Fr, IHC-P and IP. Abcam's high quality manufacturing and validation processes ensure Anti-PDGFR alpha antibody [EPR22059-270] (ab203491) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-PDGFR alpha antibody [EPR22059-270] (ab203491) has been confirmed by Western Blot testing in PDGFR alpha knockout SH-SY5Y cells ( ab275335 ). Anti-PDGFR alpha antibody [EPR22059-270] (ab203491) has 4 independent reviews from customers. Anti-PDGFR alpha antibody [EPR22059-270] (ab203491) specifically detects PDGFR alpha (UniProt ID: P16234; Molecular weight: 121kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR22059-270 - ab234965 . Antibody clone EPR22059-270 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, PE, Alexa Fluor ® 488 ( ab270085 , ab270086 , ab307855 ). The platelet-derived growth factor receptor alpha (PDGFRA) is a cell surface tyrosine kinase receptor that plays a significant role in tumor growth, invasion and angiogenesis in oncology often serving as a therapeutic target due to its overexpression in various cancers, particularly in gastrointestinal stromal tumors (GISTs), Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PDGFR alpha antibody [RM0004-3G28], Abcam, AB51875

Anti-PDGFR alpha (phospho Y742) antibody, Abcam, AB5452

Anti-PDGFR alpha (phospho Y754) antibody, Abcam, AB5460

Anti-PDGFR alpha (phospho Y849) antibody, Abcam, AB79318

Anti-PDGFR beta antibody [EPR26830-84], Abcam, AB313777

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-PDGFR beta (phospho Y751) antibody, Abcam, AB51046

HRP Anti-PDGFR alpha antibody [EPR5480], Abcam, AB305897

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .